The Shape of

Two-Step Injections

Maggie® is an easy-to-use, cartridge-based autoinjector built with SHL’s proprietary Needle Isolation Technology (NIT®). 

Join us at the 2020 PDA Universe

of  Pre-Filled Syringes and Injection Devices 

Maggie®

Transform your cartridge-based treatment with Maggie®, a two-step autoinjector built with SHL’s proprietary Needle Isolation Technology (NIT®).

Needle Isolation Technology

Close

NIT® is a unique safety solution that makes it possible for cartridges to function like traditional pre-filled syringes with staked needles. Cartridges support higher volume dosing and enable dual-chamber treatments to be built as easy-to-use autoinjectors.

Higher Volume Injections

Close

Maggie® is built with a 3mL standard ISO cartridge to support the growing trend for high-volume dosing with the emergence of biologics and biosimilars. Cartridges also offer a level of needle customization for subcutaneous or intramuscular injections.

Automated Preparation

Close

Maggie®’s NIT® sub-assembly includes a pre-attached needle. Users simply untwist the cap to attach the needle and open the fluid path. The needle cover automatically extends and the autoinjector automatically primes.

Easy 2-Step Handling

Close

Injection with Maggie® is completed with just two simple steps: uncap and inject. The autoinjector needle cover locks out after injection, shielding patients from being exposed to te needle before and after injection.

Intuitive Feedback

Close

Maggie®’s large viewing window makes it easier for patients to inspect the drug before and during injection. It also features continuous audible clicks during injection, resulting in an easier determination of dose completion.

© 2020 SHL Medical AG. SHL, the SHL logo, and all other trademarks are property of SHL Medical AG and/or its affiliates.

Intuitive Feedback

Maggie®’s large viewing window makes it easier for patients to inspect the drug before and during injection. It also features continuous audible clicks during injection, resulting in an easier determination of dose completion.

Easy 2-Step Handling

Injection with Maggie® is completed with just two simple steps: uncap and inject. The autoinjector needle cover locks out after injection, shielding patients from being exposed to the needle before and after injection.

Automated Preparation

Maggie®’s NIT® sub-assembly includes a pre-attached needle. Users simply untwist the cap to attach the needle and open the fluid path. The needle cover automatically extends and the autoinjector automatically primes.

Higher Volume Injections

Maggie® is built with a 3mL standard ISO cartridge to support the growing trend for high-volume dosing with the emergence of biologics and biosimilars. Cartridges also offer a level of needle customization for subcutaneous or intramuscular injections.

Needle Isolation Technology

NIT® is a unique safety solution that makes it possible for cartridges to function like traditional pre-filled syringes with staked needles. Cartridges support higher volume dosing and enable dual-chamber treatments to be built as easy-to-use autoinjectors.

Go to article: Home | Under the microscopeGo to article: In this issueGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ContentsGo to article: MimotopesGo to article: NewsGo to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: Nasal spray vaccine for Covid-19Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: Covid-19 clinical trials continue to rise in BrazilGo to article: BiogazelleGo to article: AstraZeneca’s Phase I / II Covid-19 vaccine trial Go to article: SwiftpakGo to article: MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1Go to article: Biesterfeld Go to article: The pharma industry briefingGo to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugsGo to article: Quality control: pharma manufacturing inspections explainedGo to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: Oxytocin: the therapeutic potential of the ‘love hormone’Go to article: AI-enabled risk detection in pharma manufacturingGo to article: Dr. Paul LohmannGo to article: Addressing the long-term effects of Covid-19Go to article: Eyes on the prize: the latest in retinitis pigmentosa gene therapiesGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: Breaking the taboo: disrupting the fertility sectorGo to article: Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough? Go to article: Nolato Company Insight Go to article: NolatoGo to article: Pharmacovigilance case intake: why the hesitation to automate?Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Zenatek Go to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue